Return to study ST000485 main page
MB Sample ID: SA024743
| Local Sample ID: | MS5035_6_120 |
| Subject ID: | SU000506 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN000751 |
|---|---|
| Analysis type | MS |
| Chromatography type | GC |
| Chromatography system | Agilent |
| Column | Agilent DB5-MS (30m × 0.25mm, 0.25um) |
| MS Type | EI |
| MS instrument type | Single quadrupole |
| MS instrument name | Agilent 5973 |
| Ion Mode | POSITIVE |
| Units | mole percent enrichment |
Chromatography:
| Chromatography ID: | CH000539 |
| Chromatography Summary: | Glucose concentration was measured every 10 min during the insulin clamp with an Analox glucose analyzer (Analox Instruments, London, U.K.). [6,6-2H2]-d-glucose enrichment in the plasma and infusate was measured using gas chromatography–mass spectrometry. As described previously, the steady-state equations of Steele et al. (29) were used to calculate the rate of glucose appearance (Ra) and disappearance (Rd). EGP was calculated as the difference between total glucose Ra and the exogenous glucose infusion rate, peripheral insulin sensitivity was assessed from the rate of glucose infusion required to maintain euglycemia during the high-dose insulin clamp, and hepatic insulin sensitivity was assessed by the extent to which EGP was suppressed from baseline to low-dose hyperinsulinemia (26). |
| Instrument Name: | Agilent |
| Column Name: | Agilent DB5-MS (30m × 0.25mm, 0.25um) |
| Chromatography Type: | GC |
